The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
The firm anticipates that it will soon launch the device as an in vitro diagnostic tool for analyzing tissue biopsies during surgeries in European hospitals.
The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
